Joachim Eeckhout’s Post

#biotech fundraisings of the week: Deals in the U.S. are slowing down after 3 crazy weeks, Europe is still registering a good number of deals 👇 🇺🇸BridgeBio | $250 million Private Placement Equity | precision medicine and gene therapy | phase 3 in transthyretin amyloidosis and autosomal dominant hypocalcemia type 1 🇩🇰Acesion Pharma | €45M ($47.56 million) Series B | cardiac disease therapies | phase 2 in cardiac arrhythmia 🇬🇧Sitryx | $39 million Venture round | immunometabolism-targeting therapies | preclinical in multiple sclerosis 🇨🇭TOLREMO therapeutics | $39 million Series A | cancer therapies | Preclinical in targeting cancer drug resistance 🇩🇰Notify Therapeutics | €5 million ($5.32 million) Seed round | non-hormonal fertility treatment | proof of concept targeting infertility 🇬🇧Crucible Therapeutics | £5 million (£6.07 million) Seed round | gene therapies | preclinical in motor neurone disease and frontotemporal dementia Want to keep track of biotech fundraising? Sign up to Labiotech.eu's newsletter!